oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 1 )

2018 ( 2 )

2017 ( 1 )

2015 ( 75 )

Custom range...

Search Results: 1 - 10 of 1459 matches for " Jacek Kasner "
All listed articles are free for downloading (OA Articles)
Page 1 /1459
Display every page Item
Celiakia rozpoznawana w wieku doros ym - problem tak e pediatryczny
Krystyna Karczewska,Jacek Kasner,Jadwiga Sulej,Daniel Sabat
Pediatria Wspó?czesna , 2006,
Abstract: Autorzy na podstawie analizy dok adnych wywiadów przeprowadzonych u pacjentów z rozpoznan w wieku doros ym celiaki , wskazuj na mo liwo wyst powania u nich postaci utajonych w dzieciństwie i m odo ci.
Próby korelacji serologicznych markerów celiakii ze stopniem zaniku kosmków jelitowych, wiekiem i p ci pacjentów z celiaki
Krystyna Karczewska,Jacek Kasner,Maria ?ukasik,Jadwiga Sulej
Pediatria Wspó?czesna , 2004,
Abstract: Celem pracy by a próba korelacji miana przeciwcia p-endomysium (IgAEmA) i p-transglutaminazie tkankowej (tTGAb) oraz stopnia zaniku kosmków na ró nych etapach diagnostyki celiakii u pacjentów w ró nym wieku. W pracy wykazano du zgodno dodatnich i ujemnych wyników badań serologicznych we wszystkich grupach diagnostycznych. Nie wykazano natomiast korelacji pomi dzy warto ciami tTGAb i IgAEmA.
Przeciwcia a przeciwko transglutaminazie tkankowej (tTG) w diagnostyce celiakii
Jacek Kasner,Krystyna Karczewska,Jadwiga Sulej,Jolanta Por?bska
Pediatria Wspó?czesna , 2002,
Abstract: Celem pracy by o porównanie wyników oznaczeń przeciwcia przeciwko transglutaminazie tkankowej -IgAtTGAb, przeciwcia przeciwko endomysium mi ni g adkich - EMA oraz oceny morfologicznej kosm-ków u pacjentów na ró nych etapach diagnostyki i leczenia celiakii. W latach 2000-2002 badaniom poddano 150 osób. W ród badanych wyró niono grup z podejrzeniem celiakii, w trakcie jej leczenia, po reprowokacji glutenem oraz grup krewnych I stopnia chorych na celiaki . Stwierdzono, e zgodno wyników oceny morfologicznej wycinków jelita cienkiego i przeciwcia EMA z wynikami IgAtTGAb uzyskano w 87,5% badanych w grupie z podejrzeniem celiakii. U pacjentów poddanych reprowokacji zgodno ta wynios a 80%. Wysokim mianom IgAEmA i znacznym zanikom kosmków towarzysz wysokie warto ci IgAtTGAb.
Trudno ci diagnostyczne w rozpoznaniu pó no ujawnionej celiakii u doros ych
Krystyna Karczewska,Jacek Kasner,Maria ?ukasik,Jadwiga Sulej
Polish Gastroenterology , 2002,
Abstract: Cel pracy: Celem pracy by o wykazanie trudno ci diagnostycznych w rozpoznawaniu celiakii u ludzi doros ych. Materia i metody: Przedmiotem retrospektywnej analizy by o 6 kobiet w wieku od 30 do 50 lat, u których w latach 1990-2001 w Klinice Pediatrii ambulatoryjnie rozpoznano celiaki . Pacjentki te przed rozpoznaniem by y wielokrotnie hospitalizowane i diagnozowane bez efektu w o rodkach internistycznych, ginekologicznych i psychiatrycznych. W wywiadzie pacjentki zg asza y objawy depresji, spadku masy cia a, przewlek e biegunki, poronienia, bóle kostno-mi niowe. Rozpoznanie celiakii oparto na stwierdzeniu obecno ci przeciwcia IgAEmA w klasie IgA i IgG oraz zaniku kosmków b ony luzowej jelita w pobranych endoskopowo bioptatach jelita. Wyniki: Zastosowana dieta przynios a szybkie ust pienie objawów chorobowych. Wnioski: Celiakia u doros ych mo e przebiega nietypowo pod mask wielu chorób.
Achalazja prze yku u 6-letniej dziewczynki
Jaros?aw Kwiecień,Jacek Kasner,Józef Dzielicki,Marcin Pi?ta
Pediatria Wspó?czesna , 2001,
Abstract: Autorzy opisuj przypadek achalazji prze yku - rzadkiego w wieku dzieci cym pierwotnego zaburzenia motoryki prze yku. Schorzenie rozpoznano u 6-letniej dziewczynki hospitalizowanej z powodu wymiotów i utraty masy cia a. Podkre lono kluczow rol manometrii prze yku w rozpoznawaniu achalazji. Omówiono tak e patofizjologi schorzenia i mo liwo ci jego leczenia.
Test of the hierarchical theory for the FQHE
M. Kasner
Physics , 1994,
Abstract: In the hierarchical theory of the fractional quantum Hall effect, the low--energy behaviour of a daughter state in the next level of the hierarchy is described by an interacting system of quasiparticles of the parent state. Taking the filled lowest Landau level as the parent state, we examine analytically the quantitative consequences of this approach for electrons interacting via a pseudopotential interaction. It is shown that the ground state energy per particle in the daughter state at a filling factor $2/3$ is exactly equal to that of a system of quasiholes in the parent state with half filling, precisely as predicted by the hierarchical approach. This is achieved with {\em only up to two--particle interactions} in the effective Hamiltonian for the quasiholes. Their single particle energy and two--particle interaction are derived. The results are generalized to the other filling factors attainable from the filled Landau level.
Electronic correlation in the quantum Hall regime
Marcus Kasner
Physics , 2002, DOI: 10.1002/1521-3889(200203)11:3<175::AID-ANDP175>3.0.CO
Abstract: Two-dimensional interacting electron systems become strongly correlated if the electrons are subject to a perpendicular high magnetic field. After introducing the physics of the quantum Hall regime the incompressible many- particle ground state and its excitations are studied in detail at fractional filling factors for spin-polarized electrons. The spin degree of freedom whose importance was shown in recent experiments is considered by studying the thermodynamics at filling factor one and near one.
Therapeutic developments in acute lymphoblastic leukemia
MacKenzie A, Kasner M
Blood and Lymphatic Cancer: Targets and Therapy , 2012, DOI: http://dx.doi.org/10.2147/BLCTT.S24990
Abstract: apeutic developments in acute lymphoblastic leukemia Review (1027) Total Article Views Authors: MacKenzie A, Kasner M Published Date November 2012 Volume 2012:2 Pages 145 - 158 DOI: http://dx.doi.org/10.2147/BLCTT.S24990 Received: 27 February 2012 Accepted: 03 July 2012 Published: 27 November 2012 Amy MacKenzie, Margaret Kasner Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA Abstract: The standard treatment of adult-onset acute lymphoblastic leukemia (ALL) is based on trials conducted 20–25 years ago and has remained largely unchanged since that time. Treatments are lengthy and have been extrapolated from successful pediatric regimens. However, adult disease is cytogenetically different from pediatric disease. Adults often have comorbidities that make completing treatment challenging, and outcomes subsequently suffer. Advances in the understanding of cytogenetics and molecular biology have led to the identification of prognostic factors, as well as offering fertile ground for the development of new therapeutics. The current research in ALL focuses on the development of monoclonal antibodies and small molecule inhibitors, as well as increasing sensitivity in monitoring minimal residual disease, improving upon current chemotherapy, and improving stem cell transplantation. This monograph reviews the current standard of care for adult ALL and the innovations in clinical investigation that aim to improve the future for adults who suffer from this disease. The adult population is in great need of similar advances and stands to benefit tremendously from the research discussed in this review. The challenges of sustainable remission and reduced morbidity and mortality in treatment remain to be surmounted. The aggressive efforts of current clinical trials that are investigating novel therapies both alone and with standard treatment offer hope for adults that is slowly beginning to be realized.
Therapeutic developments in acute lymphoblastic leukemia
MacKenzie A,Kasner M
Blood and Lymphatic Cancer: Targets and Therapy , 2012,
Abstract: Amy MacKenzie, Margaret KasnerDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USAAbstract: The standard treatment of adult-onset acute lymphoblastic leukemia (ALL) is based on trials conducted 20–25 years ago and has remained largely unchanged since that time. Treatments are lengthy and have been extrapolated from successful pediatric regimens. However, adult disease is cytogenetically different from pediatric disease. Adults often have comorbidities that make completing treatment challenging, and outcomes subsequently suffer. Advances in the understanding of cytogenetics and molecular biology have led to the identification of prognostic factors, as well as offering fertile ground for the development of new therapeutics. The current research in ALL focuses on the development of monoclonal antibodies and small molecule inhibitors, as well as increasing sensitivity in monitoring minimal residual disease, improving upon current chemotherapy, and improving stem cell transplantation. This monograph reviews the current standard of care for adult ALL and the innovations in clinical investigation that aim to improve the future for adults who suffer from this disease. The adult population is in great need of similar advances and stands to benefit tremendously from the research discussed in this review. The challenges of sustainable remission and reduced morbidity and mortality in treatment remain to be surmounted. The aggressive efforts of current clinical trials that are investigating novel therapies both alone and with standard treatment offer hope for adults that is slowly beginning to be realized.Keywords: adult acute lymphoblastic leukemia, Philadelphia chromosome, monoclonal antibodies, molecular pathways
Informed Consent: The Rate-Limiting Step in Acute Stroke Trials
Scott E. Kasner
Frontiers in Neurology , 2011, DOI: 10.3389/fneur.2011.00065
Abstract: Successful implementation of a randomized clinical trial (RCT) for neuro-vascular emergencies such as cerebral infarction, intracerebral hemorrhage, or subarachnoid hemorrhage is extraordinarily challenging. Besides establishing an accurate, hyper-expedited diagnosis among many mimics in a person with acute neurological deficits, informed consent must be obtained from this vulnerable group of patients who may be unable to convey their own wishes, grasp the gravity of their situation, or give a complete history or examination. We review the influences, barriers, and factors investigators encounter when providing established and putative stroke therapies, and focus on informed consent, the most important research protector of human subjects, as the rate-limiting step for enrollment into acute stroke RCTs. The informed consent process has received relatively little attention in the stroke literature, but is especially important for stroke victims with acute cognitive, aural, lingual, motor, or visual impairments. Consent by a surrogate may not accurately reflect the patient’s wishes. Further, confusion about trial methodology, negative opinions of placebo-controlled studies, and therapeutic misconception by patients or surrogates may impede trial enrollment and requires further study. Exception from informed consent offers an opportunity that is rarely if ever utilized for stroke RCTs. Ultimately, advancing the knowledge base and treatment paradigms for acute stroke is essential but autonomy, beneficence (non-malfeasance), and justice must also be carefully interwoven into any well-designed RCT.
Page 1 /1459
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.